Kornimate/medical-research-clean huggingface dataset:
effect of papillary epinephrine spraying on post-ercp pancreatitis in patients received rectal indomethacin

Conditions: Pancreatitis; Endoscopic Retrograde Cholangiopancreatography

Summary: acute pancreatitis is the most common and feared complication of ercp, occurring after 1% to 30% of procedures. it accounts for substantial morbidity and represents a substantial cost to health-care systems. european society of gastrointestinal endoscopy and japanese society of hepato-biliary-pancreatic surgery guidelines and recently large-scale rct recommended routine use of nsaids indomethacin rectally before ercp. nonsteroidal anti-inflammatory drugs (nsaids) have been shown to inhibit prostaglandin synthesis, phospholipase a2 activity, and neutrophil/endothelial cell attachment, which is believed to play a key role in the pathogenesis of acute pancreatitis. other possible mechanisms have been suggested in the occurrence of pancreatitis. papillary edema caused by manipulations during cannulation or endoscopic treatment has received the most attention. the papillary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. topical application of epinephrine on the papilla may reduce papillary edema by decreasing capillary permeability or by relaxing the sphincter of oddi. a meta-analysis (including 2 existing rcts and post-hoc analysis of our previous study) of papillary epinephrine spraying compared with saline spraying or no intervention indicates a potential relative risk reduction of pep (rr 0.34, 95%ci 0.19-0.61). papillary epinephrine spraying may be an inexpensive and convenient alternative for prevention of post-ercp pancreatitis. a large pragmatic rct to determine whether routine using papillary epinephrine spraying can reduce post-ercp pancreatitis is needed.


Eligibility criteria:
inclusion criteria: * 18-80 years old patients planned for ercp. exclusion criteria: * contraindications to ercp * allergy to epinephrine or nsaids * not suitable for pre-ercp indomethacin (received nsaids within 7 days before the procedure; gastrointestinal hemorrhage within 4 weeks; renal dysfunction \[cr \>1.4mg/dl=120umol/l\]; presence of coagulopathy before the procedure) * previous biliary sphincterotomy without planned pancreatic duct manipulation * ercp for biliary stent removal or exchange without planned pancreatic duct manipulation * acute pancreatitis within 3 days before the procedure * unwilling or inability to provide consent * pregnant or breastfeeding women

Keywords: ercp, post-ercp pancreatitis, indomethacin, epinephrine
chronic pain after thoracotomy, an incidence study in a single surgical center

Conditions: Thoracotomy; Chronic Pain

Summary: investigation of chronic pain frequency after thoracotomy for lung cancer. risk factors for development of chronic pain are investigated. questionnaire survey.


Eligibility criteria:
inclusion criteria: * thoracotomized patients exclusion criteria: * mental incapacity, * poor understanding of french, * pre-existing chronic pain before surgery, * redo-surgery
mini gastric bypass vs roux eny gastric bypass

Conditions: Gastric Bypass

Summary: the primary aim of this research project is to assess the safety and efficacy of the mgb operation in the uk

the main aim of this project is to develop an ideal bariatric/metabolic surgery operation. the ideal features are highly safe operation, revisable, reversible, extremely effective, short operative time, short hospital stay, cost-effective, no long-term complications and acceptable to the patients. mini gastric bypass/one anastomosis gastric bypass mgb/oagb is relatively a new bariatric /metabolic surgery operation that is increasing in popularity and currently more than 60,000 operations are performed worldwide. only 125 mgb operations are published from uk. no previous rct to date in the uk to test the new operation although rct was done in taiwan 2005 and showed that mgb is not inferior to the roux eny gastric bypass rygb. this research project is assessing the outcomes of this operation and opening the doors to understand its effects and how it works compared to the standard rygb. the possible development in the project is to study the hormonal changes after the mgb.

Eligibility criteria:
inclusion criteria: * they have a bmi of 40 kg/m2 or more, or between 35 kg/m2 and 40 kg/m2 and other significant disease (for example, type 2 diabetes or high blood pressure) that could be improved if they lost weight. * all appropriate non-surgical measures have been tried but the person has not achieved or maintained adequate, clinically beneficial weight loss. * the person has been receiving or will receive intensive management in a tier 3 service. * the person is generally fit for anaesthesia and surgery. * the person commits to the need for long-term follow-up exclusion criteria: * not meeting the eligibility criteria * under 18s

Keywords: mini gastric bypass roux en-y gastric bypass bariatric surgery type 2 diabetes
treatment of chronic and non-chronic wounds in patients with recessive dystrophic epidermolysis bullosa using helicoll collagen dressings versus standard of care

Conditions: Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa

Summary: the purpose of this study is to test the effectiveness of helicoll (a collagen wound dressing) in treating chronic and non-chronic wounds of recessive dystrophic epidermolysis bullosa (rdeb) patients. helicoll will be compared to standard wound dressings.


Eligibility criteria:
inclusion criteria: 1. written consent must be obtained from subjects over age 18, or from a parent or legally authorized representative if subject is under 18. assent will be obtained from subjects age 7 - 17. 2. subjects with a clinical diagnosis of rdeb by a dermatologist. 3. have at least three target wounds that meet the following criteria: * one chronic wound, of approximately 6 months or more duration. if the subject has an additional chronic wound of similar size and duration, this additional wound will be treated with standard dressings and followed in the study. a wound in an area that consistently heals and then breaks down again will be considered a chronic wound. * two non-chronic wounds, of approximately 3 months or less duration, of similar size, and able to be dressed separately. both wounds should have approximately the same duration. all wounds must be: * open, and not scabbed or crusted over * not actively infected * not requiring surgical intervention 4. a parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits (for minor subjects). 5. the subject or caregiver (or a parent or legally authorized representative for subjects under 18) must be able to follow instructions. 6. subject must be age 7 or older. exclusion criteria: 1. inability to travel to stanford for study visits. 2. complicating illness as determined by study investigators to be exclusionary including any infection requiring systemic antibiotics. 3. presence or history of squamous cell carcinoma at target wound site. 4. known bovine (cow) or ovine (sheep) sensitivity. 5. therapy with an investigational agent during the study.
safety and efficacy of combined sedation with midazolam and dexmedetomidine in icu patients

Conditions: Delirium

Summary: it is well known that icu patients need sedation. now no ideal sedation drug existed and every sedation drug has its advantage and disadvantage,so combined sedation may use the advantage and avoid the disadvantage of the sedation drug according to the patients'condition. until now, there is rare study about the combined sedation or sequenced sedation of different sedation drug.the purpose of the study is to explore the value of combined sedation with midazolam and dexmedetomidine compared to single drug sedation in icu, so as to seek an ideal sedation protocol that could reduce the cost of treatment,obtain the appropriate sedation not under sedation or over sedation,reduce the incidence of delirium, reduce the adverse event of sedation.


Eligibility criteria:
inclusion criteria: 1. icu patients needing sedation 2. 18 years or older 3. mechanically ventilated for less than 96 hours prior to start of study drug. exclusion criteria: 1. trauma and burn patients as admitting diagnosis. 2. dialysis of all types. 3. pregnant or lactation. 4. neuromuscular blockade other than for intubation. 5. epidural or spinal analgesia. 6. general anesthesia prior to or planned after the start of study drug infusion 7. serious central nervous system pathology(acute stroke, uncontrolled seizures,severe dementia). 8. acute hepatitis or severe liver disease (child-pugh class c). 9. unstable angina or acute myocardial infarction. 10. left ventricular ejection fraction less than 30%,heart rate less than 50/min. 11.second or third degree heart block. 12.allergy to the study drug. 13.systolic blood pressure less than 90 mm hg despite continuous infusions of 2 vasopressors before the start of study drug infusion. 14. patients with renal insufficiency were randomized and treated; however, patients were discontinued if they required dialysis.

Keywords: intensive care unit mechanical ventilation combined sedation
immunogenicity and safety of a combined vaccine to prevent measles, mumps, rubella and chickenpox diseases

Conditions: Measles; Rubella; Mumps; Varicella

Summary: this is a study to evaluate the immunogenicity and safety of glaxosmithkline (gsk) biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.

this study included an active control group who received the licensed priorix (measles, mumps, rubella \[mmr\] vaccine).

Eligibility criteria:
inclusion criteria: * a male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination. exclusion criteria: * history of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial * planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

Keywords: prophylaxis measles, mumps, rubella and chickenpox
consequences of intensified handwash and hand disinfection among children during the covid19 pandemic

Conditions: Hand Eczema; Hand Dermatitis; Covid19

Summary: during the covid-19 pandemic after reopening of the country, school, kindergarten and daycare, children have been obligated to do frequent handwash. the study group wished to investigate whether this has had implications on symptoms of dry, red, itchy or sore hands and hand eczema. the investigation was performed within the first and second week after reopening by questionnaires distributed to parents electronically via schools, kindergartens and daycare facilities electronic platforms.

during the covid-19 pandemic denmark closed down, including schools, kindergartens and daycare. after reopening of the country 5 weeks later obligatory frequent handwash was a requirement from the government and routines has been implemented at all reopened schools, kindergartens and daycare. the study group wished to investigate whether this has had implications on symptoms of dry, red, itchy or sore hands and hand eczema. also the study group wished to investigate if frequency or use of hand disinfection mattered. the investigation was performed within the first and second week after reopening by questionnaires distributed to parents electronically via schools, kindergartens and daycare electronic platforms. the questionnaire included 20 questions on demographics, frequency of hand wash and use of disinfectants, current and previous symptoms of eczema, atopic dermatitis and dispositions.

Eligibility criteria:
inclusion criteria: * all children returned to daycare, kindergarten or school after covid19 close down of the country exclusion criteria: * none

Keywords: dermatitis hand wash hand disinfection children pediatric
safety, tolerability, and efficacy of nbi-98854 for the treatment of pediatric subjects with tourette syndrome

Conditions: Tourette Syndrome

Summary: this is a phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of nbi-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with ts.


Eligibility criteria:
inclusion criteria: 1. have a clinical diagnosis of tourette syndrome (ts) 2. have at least moderate tic severity 3. have ts symptoms that impair school, occupational, and/or social function 4. if using maintenance medication(s) for ts or ts spectrum diagnoses (e.g. obsessive-compulsive disorder \[ocd\], attention-deficit hyperactivity disorder \[adhd\]), be on stable doses 5. be in good general health 6. adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen 7. subjects of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study exclusion criteria: 1. have an active, clinically significant unstable medical condition within 1 month prior to screening 2. have a known history of long qt syndrome or cardiac arrhythmia 3. have a known history of neuroleptic malignant syndrome 4. have a cancer diagnosis within 3 years prior to screening (some exceptions allowed) 5. have an allergy, hypersensitivity, or intolerance to vmat2 inhibitors 6. have a blood loss ≥250 ml or donated blood within 30 days prior to screening 7. have a known history of substance dependence, substance (drug) or alcohol abuse 8. have a significant risk of suicidal or violent behavior 9. have initiated comprehensive behavioral intervention for tics (cbit) during the screening period or at baseline or plan to initiate cbit during the study 10. have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than nbi-98854) during the study
efficacy of simplified two drug kaletra regimen vs. kaletra triple drug standard of care regimen in treatment naïve hiv infected patients

Conditions: HIV Infection

Summary: the purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified kaletra dual agent therapy as initial treatment for hiv infection, relative to a kaletra three drug standard of care reference arm.


Eligibility criteria:
inclusion criteria: * hiv positive * \>18 years of age * hiv rna\> 400 copies/ml * any cd 4 cell count * antiretroviral naïve * no acute illness exclusion criteria: -

Keywords: lopinavir ritonavir kaletra tenofovir hiv infection treatment naive
postoperative virtual clinical encounters

Conditions: Pelvic Organ Prolapse

Summary: postoperative follow up is necessary following any surgical procedure and has been conducted in the same manner since the field of surgery began. the study will determine feasibility and patient satisfaction of innovative postoperative virtual clinical encounters utilizing mobile video conference technology for women undergoing pelvic reconstructive surgery through a randomized controlled trial.

this will be a prospective randomized control study comparing postoperative virtual clinical encounters versus traditional in-office postoperative visits in women undergoing pelvic reconstructive surgery. the postoperative experiences of both groups will be assessed via surveys. virtual clinical encounter group: - receive video-conference call from office nurse 48-72 hours post discharge from hospital - receive video-conference call from fellow and/or attending physician approximately 30 days (4-6 weeks) from surgery -- complete telephone survey one day later - have in-office postoperative visit with fellow and/or attending physician approximately 90 days (10-12 weeks) from surgery -- fill out surveys after office visit traditional office group: - receive telephone call from office nurse 48-72 hours post discharge from hospital - have in-office postoperative visit with fellow and/or attending physician approximately 30 days (4-6 weeks) from surgery -- complete telephone survey one day later - have in-office postoperative visit with fellow and/or attending physician approximately 90 days (10-12 weeks) from surgery -- fill out surveys after office visit

Eligibility criteria:
inclusion criteria: * undergoing surgery for pelvic organ prolapse * age greater than 18 * access to a smartphone * access to high speed internet access (via 4g or 3g on their smartphone or high speed wi-fi) * signed up for mypennmedicine web portal * ability to download mychart mobile application * pennsylvania hospital subject: nj or pa resident, hup \& presbyterian hospital subject: pa resident exclusion criteria: * pregnancy * inability to read, speak or understand english * isolated midurethral sling procedure * extraperitoneal vaginal colpopexy with uphold mesh
multicenter registration study on allergic bronchopulmonary aspergillosis

Conditions: Allergic Bronchopulmonary Aspergillosis

Summary: to understand the current diagnosis and treatment status of abpa patients, observe their clinical characteristics, prognosis, and treatment outcomes, and identify the relevant factors for poor prognosis in patients.


Eligibility criteria:
inclusion criteria: meeting the diagnosis of abpa according to the abpa diagnostic criteria specified by the isham-abpa working group in 2024 exclusion criteria: abpa patients who are not first diagnosed in the center

Keywords: cohort study
ddx3x syndrome -the seaver autism center for research and treatment is characterizing ddx3x-related neurodevelopmental disorders using genetic, medical, and neuropsychological measures.

Conditions: DDX3X; Mental Retardation, X-linked 102; Autism Spectrum Disorder

Summary: ddx3x syndrome is a genetic cause of intellectual disability and other neurologic features including, in some cases, autism. variants in the ddx3x gene are thought to account for 1-3% of unexplained intellectual disability in females, making it one of the more common causes of intellectual disability.this study seeks to characterize ddx3x-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

subjects with a variant in the ddx3x gene will be asked to complete a battery of developmental, behavioral and medical assessments to better characterize gene-related neurodevelopmental deficits. this series of assessments takes place over the course of a three-day period. it includes the autism diagnostic observation schedule (ados), parent interviews regarding developmental history and behavior, a psychiatric evaluation, a neurology assessment, as well as a clinical genetic evaluation that includes a physical and vitals exam. affected individuals, as well as biologically related siblings, will also undergo a series of sensory assessments, including a research eeg, visual evoked potential, and an eyetracking assessment. family members present for the visit will also be asked to provide a blood and/or saliva sample for research genetics.

Eligibility criteria:
inclusion criteria: * eligible participants must have a documented variant affecting the ddx3x gene that the research team determines to be likely or definitely pathogenic. * eligible participants must be at least 2 years of age. exclusion criteria: * none

Keywords: ddx3x intellectual disability global developmental delay neurodevelopmental deficits developmental disability
comparing lipiodol/ethanol with drug-eluting beads (deb) for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: chemoembolization of hepatocellular carcinoma lesions is an accepted and frequently used method for the palliative or curative treatment of these lesions. these attempts are being made to make these patients a better candidate for liver transplant or to provide palliation for their condition.

this is a randomized prospective study with two arms, drug-eluting beads with doxorubicin (deb) and lipiodol ethanol mixture (lem), with the goal to show non-inferiority of lem, which if true will facilitate a simple alternative to debs. patients will be randomized to one arm of the study and will remain in that arm if they need to have more embolization in the future. both of the mentioned methods (deb and lem) fall within the standard of care.

Eligibility criteria:
inclusion criteria: * child-pugh class a or b * biopsy proven hcc or hypervascular mass per european association for the study of the liver (easl) criteria * patient not a candidate for surgical resection or percutaneous ablation * age \> 18 years old and able to consent exclusion criteria: * child-pugh class c * model for end-stage liver disease (meld) score \>16 * extrahepatic disease * bilateral or main portal vein thrombus * total bilirubin \> 2.2 * serum albumin \< 2.6 * life expectancy \< 2 months * uncorrected inr \> 2 * eastern cooperative oncology group (ecog) status \> 2 * tumor burden \> 50% liver volume * hepatofugal portal venous flow
rectal versus oral diclofenac sodium in relieving post episiotomy pain

Conditions: Episiotomy Wound

Summary: current study aims to compare oral diclofenac sodium with it's rectal form for analgesia of pain after episiotomy.

* episiotomy is a surgical incision of the perineum and the posterior vaginal wall. * it can be done at a 60 degree angle from the vulva towards the anus or at an angle from the posterior end of the vulva. * usually under local anesthetic and is sutured after delivery. * it is done during second stage of labor to enlarge the opening for the baby to pass through to avoid soft-tissue tearing which may involve the anal sphincter and rectum. * perineal pain after episiotomy has immediate and long-term negative effects for women and their babies. these effects can interfere with breastfeeding and the care of the infant. * usually women undergo episiotomy need a good analgesic to overcome pain resulting from the analgesic. * previous study by faiza shafi, shazia sayed, naheed bano, rizwana chaudhri, holy family hospital, rawalpindi, pakistan, the study was published in journal of rawalpindi medical college and concluded that rectal diclofenac should be further promoted , for pain relief, in women following episiotomy.

Eligibility criteria:
inclusion criteria: 1. age: 20:35 years. 2. primigravidae as elective procedure. 3. face to pubis delivery. 4. big baby. 5. narrow pelvic arch. 6. elderly primigravida. 7. old perineal scar as episiotomy or perineorrhaphy. 8. manipulative delivery. 9. to cut short second stage cases such as pre eclampsia. 10. premature baby. 11. fetal distress. exclusion criteria: 1. more than 35 years. 2. pelvic inflammatory disease.

Keywords: episiotomy